CureVac

Country

Ownership: -

Employees: 1.1K

Market Cap: -

Website

Introduction: CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Clinical Trials

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Phase 1

Recruiting

Conditions: Glioblastoma

Interventions: Biological: CV09050101 mRNA vaccine (CVGBM) 6 μg
Biological: CV09050101 mRNA vaccine (CVGBM) 12 μg
Biological: CV09050101 mRNA vaccine RDE 100 μg
Biological: CV09050101 mRNA vaccine (CVGBM) 25 μg
Biological: CV09050101 mRNA vaccine (CVGBM) 100 μg
Biological: CV09050101 mRNA vaccine (CVGBM) 50 μg

First Posted Date: 2023-07-10

Last Posted Date: 2024-08-15

Lead Sponsor: CureVac

Target Recruit Count: 16

Registration Number: NCT05938387

Locations: 🇧🇪
Universitair Ziekenhuis Brussel - PPDS, Brussel, Belgium
🇩🇪
University Clinic Regensburg, Regensburg, Bayern, Germany
🇩🇪
Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany

and more 11 locations

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: CVSQIV

First Posted Date: 2022-02-23

Last Posted Date: 2023-06-06

Lead Sponsor: CureVac

Target Recruit Count: 240

Registration Number: NCT05252338

Locations: 🇵🇦
International Vaccination and Research Center (CEVAXIN) Panama Clinic, Ramon H Jurado Street, Pacific Center, Level 12, Panama, Panama
🇵🇦
Unidad de Investigación Clínica INDICASAT AIP / Hospital Paitilla, Panama, Panama
🇵🇦
International Vaccination and Research Center (CEVAXIN) Avenida Mexico, 33 Street, Panama, Calidonia, Panama City, Panama

COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

Phase 3

Terminated

Conditions: Coronavirus
SARS-CoV-2
Covid19
Severe Acute Respiratory Syndrome

Interventions: Biological: CVnCoV Vaccine

First Posted Date: 2021-04-26

Last Posted Date: 2022-05-13

Lead Sponsor: CureVac

Target Recruit Count: 129

Registration Number: NCT04860258

Locations: 🇧🇪
Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman, Liège, Belgium
🇧🇪
Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium
🇧🇪
Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 1 locations

A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19

Phase 3

Withdrawn

Conditions: Covid19
SARS-CoV-2
Coronavirus
Severe Acute Respiratory Syndrome

Interventions: Biological: CVnCoV Vaccine

First Posted Date: 2021-04-09

Last Posted Date: 2021-08-20

Lead Sponsor: CureVac

Registration Number: NCT04838847

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Phase 3

Completed

Conditions: SARS-CoV-2
Coronavirus
Severe Acute Respiratory Syndrome
Covid19

Interventions: Biological: CVnCoV Vaccine
Drug: Placebo

First Posted Date: 2020-12-19

Last Posted Date: 2023-10-06

Lead Sponsor: CureVac

Target Recruit Count: 2357

Registration Number: NCT04674189

Locations: 🇩🇪
Universitätsmedizin der Johannes-Gutenberg-Universität Mainz Langenbeckstr. 1, Mainz, Germany

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Phase 2

Completed

Conditions: Covid19
SARS-CoV-2

Interventions: Biological: Placebo
Biological: CVnCoV
Biological: Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program

First Posted Date: 2020-12-03

Last Posted Date: 2024-04-29

Lead Sponsor: CureVac

Target Recruit Count: 39680

Registration Number: NCT04652102

Locations: 🇵🇦
Centro de Vacunacion Internacional - CEVAXIN Avenida Mexico, Panama city, Panama
🇵🇪
Hospital de Chancay y Servicios básicos de Salud, Chancay, Peru
🇵🇪
Centro de Investigación para ensayos Clínicos UPCH, Lima, Peru

and more 43 locations

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Phase 2

Completed

Conditions: Coronavirus
Severe Acute Respiratory Syndrome
SARS-CoV-2
Covid19

Interventions: Biological: CVnCoV 6 μg
Biological: CVnCoV 12 μg
Biological: Hepatitis A vaccine
Biological: CVnCoV 12μg
Biological: Pneumococcal vaccine

First Posted Date: 2020-08-17

Last Posted Date: 2023-09-28

Lead Sponsor: CureVac

Target Recruit Count: 668

Registration Number: NCT04515147

Locations: 🇵🇪
Instituto de Investigación Nutricional, Lima, Peru
🇵🇦
Centro de vacunación internacional - CEVAXIN Panama Clinic, Panama city, Panama

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Phase 1

Completed

Conditions: Severe Acute Respiratory Syndrome
Coronavirus
SARS-CoV-2
COVID-19

Interventions: Biological: CVnCoV Vaccine
Drug: Placebo

First Posted Date: 2020-06-26

Last Posted Date: 2023-01-30

Lead Sponsor: CureVac

Target Recruit Count: 280

Registration Number: NCT04449276

Locations: 🇧🇪
Universitair Ziekenhuis Ghent, Ghent, Belgium
🇩🇪
Medical University Hannover (MHH), Hannover, Germany
🇩🇪
University Hospital Tübingen Institut für Tropenmedizin, Tübingen, Germany

and more 1 locations

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Rabies

Interventions: Biological: Rabipur®
Biological: Rabies mRNA vaccine CV7202

First Posted Date: 2018-10-19

Last Posted Date: 2024-12-19

Lead Sponsor: CureVac

Target Recruit Count: 53

Registration Number: NCT03713086

Locations: 🇩🇪
Department of Infectious Diseases and Tropical Medicine (DITM), Medical Center of the University of Munich, Munich, Bavaria, Germany
🇧🇪
University Hospital Ghent, Ghent, Belgium

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Phase 1

Conditions: Melanoma (Skin)
Squamous Cell Carcinoma of the Skin
Carcinoma, Squamous Cell of Head and Neck
Carcinoma, Adenoid Cystic

Interventions: Biological: CV8102 + anti-PD-1 therapy
Biological: CV8102

First Posted Date: 2017-09-25

Last Posted Date: 2021-11-04

Lead Sponsor: CureVac

Target Recruit Count: 98

Registration Number: NCT03291002

Locations: 🇷🇺
Center for Personalized Oncology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
🇦🇹
Universitätsklinik für Dermatologie der Paracelsus medizinischen Privatuniversität Salzburg, Salzburg, Austria
🇦🇹
Medical University of Graz, Graz, Austria

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy